Archief

AB04030

12 april 2021

A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of Masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg…

AB11002

A prospective, multicenter, randomised, open-label, active controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor…

ACT NY ESO synoviosarcoom

Samenvatting In het AVL is de TCR studie voor NY ESO pos synoviosarcoom patiënten open. Gemetastaseerde synoviosarcoom patiënten voor eerste lijns/tweedelijns behandeling kunnen geïncludeerd worden. Er is in…

Anthos studies met factor IX remmers

1 mei 2023

ANZadapt studie

8 juni 2023

ANZadapt studie Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer: the ANZadapt study Samenvatting De ANZadapt studie is…

Apa Enza Short studie

8 april 2024

Studiecoördinator Bij vragen of verwijzingen graag contact opnemen met de studiecoördinator. Dr. M. van Kruchten Afdeling Medische Oncologie Tel: 050 3612821 (secretariaat Oncologie) E-mail: m.van.kruchten@umcg.nl

Archipelago – OncoLifeS

18 maart 2022

Studiecoördinator Bij vragen of verwijzingen graag contact opnemen met de studiecoördinator. Prof. Dr. A.K.L. Reyners Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: a.k.l.reyners@umcg.nl

ARTFORCE

12 april 2021

Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE. A randomized study with concomitant cisplatin and standard or adaptive high dose radiotherapy for advanced head and neck…

ASCENT-03

4 april 2023

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose…

ASCENT-04

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic…

ASPEN-04

1 april 2022

Een fase 2 onderzoek naar ALX148 in combinatie met pembrolizumab en chemotherapie bij patiënten met gevorderd plaveiselcelcarcinoom van het hoofd en de hals (ASPEN-04, AT148004) Samenvatting Dit is…

BI-1403-0002

24 januari 2023

A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors Protocol:…

BI-1403-0002

A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors Protocol:…

CA209-8UU Imaging

PD-L1 PET imaging in patients with an inoperable melanoma or NSCLC with brain metastasis and eligible for treatment with nivolumab. CA209-8UU imaging Protocolnummer: 2016255-322 EudraCT nummer: 2016-002308-22 METc…

CAIRO 4

The role of surgery of the primary tumour with few or -absent symptoms in patients with synchronous unresectable metastases of colon cancer, a randomized phase III study. METcnummer:…

CAIRO5

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases. CAIRO5, a randomized phase 3 study of the Dutch Colorectal Cancer Group (DCCG) Eudract nummer: 2013-005435-24 METc…

CD8 PET imaging studie (GENENTECH)

Een fase 1-2 immunoPET imaging studie met ZED88082A/CED88004S in patiënten voor en tijdens behandeling met 1) MPDL3280A of 2) PD-1 antilichaam met of zonder ipilimumab. Protocolnummer: Eudract nummer:…